The proportion of proliferating tumour cells in a tumour ('growth fraction') was estimated in 30 patients with primary ovarian carcinoma, using monoclonal antibody Ki-67 which reacts with a nuclear antigen present only in proliferating cells. A positive correlation between the 'growth fraction' and both the clinical stage and histological grade of the tumours was observed. A high 'growth fraction' was observed in advanced, metastatic and poorly differentiated tumours and a low 'growth fraction' with early stage, well-differentiated tumours. This information which has not been available previously to clinicians may be of practical value for determining the prognosis, and influencing treatment recommendation.
No takes yet. Share an insight, caveat, or question.
Wong et al. (1989) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: